CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Isabella Piassi Godói, Livia Lovato Pires Lemos, Vânia Eloisa de Araújo, Braúlio Cesar Bonoto, Brian Godman, Augusto Afonso Guerra Júnior

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)
158 Downloads (Pure)


INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

Original languageEnglish
Number of pages16
JournalJournal of Comparative Effectiveness Research
Early online date13 Jan 2017
Publication statusE-pub ahead of print - 13 Jan 2017


  • dengue
  • meta-analysis
  • systematic review
  • vaccines

Cite this